Dr. Helmut M. Schuehsler

Dr. Schuehsler serves as Chairman and CEO of TVM Capital Healthcare in Dubai and Singapore. TVM Capital Healthcare is a private equity investment platform created in 2009 focused on investing in and building transformational healthcare companies in the fast-growing emerging economies of the Middle East and Southeast Asia, including the expansion of Western companies into these regions. TVM Capital Healthcare closed its latest oversubscribed growth capital fund with a focus on Saudi Arabian healthcare transformation in the summer of 2024 at USD 254M and intends to mobilize total capital of more than USD 500M for about 10 portfolio companies in sub-sectors such as pharma, device, and diagnostics manufacturing, as well as single specialty clinics such as post-acute and chronic care, home health and disease management, reproductive medicine, oncology, cardiology and the rapidly growing field of digital health solutions.


In the Middle East, Dr. Schuehsler served as chairman or director of several healthcare growth companies since 2010, both in the field of specialized clinics as well as medical device manufacturing.


Since joining the original TVM Capital company (Techno Venture Management GmbH) in 1990 in Munich, Dr. Schuehsler has led the company through several transitions of ownership and strategy and has been the deal maker on more than 30 direct investments in life science and healthcare companies in Europe, the U.S., and the Middle East. During his tenure with TVM Capital from 1990-2012, he led the life science investment practice, raised more than US$1.2bn in committed capital, oversaw more than 100 investments in the health industry by teams out of Munich and Boston and had more than 50 IPOs and 30 M&A exit transactions in the portfolio. In this position as Managing Partner, he developed TVM Capital into the leading and largest life science investor in Germany in the 1990s, led the development of the firm into one of the leading pan- European and transatlantic investors. TVM Capital was for many years among the top ten investors in life sciences on the East Coast.


Starting in 2007, he spearheaded the expansion of the firm into the field of emerging market healthcare private equity which was domiciled in Dubai in 2009 and expanded to Singapore in late 2020. Both regional teams are currently fundraising for regional healthcare growth capital funds.


In terms of industry representation, from 2003 to 2007, Dr. Schuehsler served as Chairman of the Professional Standards Committee of the European Private Equity and Venture Capital Association (EVCA, now “Invest Europe”), where he led a team of up to 10 finance, audit and legal specialists as well as industry practitioners in the development or improvement of PE/VC industry guidance documents such as the Code of Conduct. In 2007, he was elected Chairman of EVCA. In 2014-2017, he also served on the Steering Committee of the MENA Private Equity Association.


On the technology commercialization and financing side, Dr. Schuehsler served as a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany, was a board member of Max-Planck Innovation GmbH in Munich for more than 10 years and was a member of the Selection Committee for the Technology Pioneers program and the Steering Committee of the Entrepreneurship and Successful Growth Research Program of the World Economic Forum for several years.

Hoda Abou-Jamra

Hoda Abou-Jamra is the Co-Founder and Managing Partner of TVM Capital Healthcare and is currently based in Singapore. She played a pivotal role in establishing the firm’s presence in the Middle East in 2007, leading the launch of one of the first healthcare-focused private equity investment platforms in the MENA region. Recognizing similar structural needs and opportunities in Asia, Hoda later expanded the business to Singapore to advance access to high-quality, affordable specialty healthcare in Southeast Asia, culminating in the first close of the TVM Healthcare Southeast Asia Fund in 2025.

In 2025, Hoda was named one of the “Top 15 Women Leaders in the Middle East” by the Women Leaders Summit KSA. Her experience building cross-border healthcare platforms across the U.S., Europe, the Middle East, and Southeast Asia has shaped TVM Capital Healthcare into a successful emerging markets investor with a dual mandate: strong commercial value creation and measurable social impact with top quartile financial track record.

Hoda has been instrumental in using her global networks to build bridges between healthcare ecosystems in the U.S. and Europe and fast-growing markets across the Middle East and Southeast Asia, enabling the transfer of know-how, technology, and operating models to improve patient outcomes at scale.

Hoda currently serves on the boards of Manzil Healthcare Services (UAE) and Amecath Medical Technologies, a medical devices company. She is also the Chairperson of Alina Vision, an ophthalmology platform based in Vietnam, and a Board Member of 2X Global, where she leads TVM Capital Healthcare’s commitment to the 2X Challenge, advancing gender-smart investing and women’s economic participation.

She is an active contributor to global networks focused on women’s leadership and healthcare innovation, including 100 Women in Finance, PEWIN, WBL – Women Leading in Healthcare, the Dubai Business Women Council, and PhiSB. She also co-founded and served as the founding Chair of the 30% Club MENA, advocating for gender diversity in corporate governance.

Hoda has been appointed to the International Advisory Council of Mass General Brigham (Boston), one of the leading academic medical systems in the United States. She holds a degree from Northeastern University’s Bouvé College of Health Sciences, School of Pharmacy

Tristan de Boysson

Tristan de Boysson joined the firm as Managing Partner in H2 2020, adding more than 20 years of experience in Private Equity gained as CEO of Amanat Holdings PJSC, the largest integrated healthcare and education investment company in the MENA region listed on the Dubai Financial Market, and, from 1998 to 2018, as Managing Director at Investcorp, a leading global manager of alternative investments.

 

He joined Investcorp initially as a member of the European Private Equity team based in London where he led, executed, managed and realized private equity transactions across Europe and then transferred to Bahrain in 2008 where he launched Investcorp’s first Middle East focused fund and, as Co-Head of Investcorp Private Equity MENA, deployed over $1.5 billion of capital in 16 majority and minority private equity transactions in the MENA region and in Turkey, in the Healthcare, Consumer & Retail, Industrial and Technology sectors.

 

Tristan worked previously at McKinsey & Company’s Paris office where, as an Associate Principal, he advised clients on strategy/valuation, organizational and operational improvement issues. He holds a Master’s degree in Economics from ESSEC – Paris and an MBA from INSEAD.

Orhan Osmansoy

Orhan Osmansoy has over 20 years of experience in the fields of private equity, merchant banking, and equity capital markets at leading financial services firms. Prior to his current role he was a Managing Director at Frontier Management Group, where he worked with the broader team at Apollo Global Management to source and evaluate private equity and private credit transactions and present investment ideas across a wide range of transaction types including leveraged buyouts, mezzanine financings, and structured purchases.

 

Prior to joining Frontier, Orhan held Board-level and senior responsibility for NAC Ventures SPC, a Kuwaiti creditor-owned restructuring SPV. He had oversight of NAC’s USD 700 million portfolio, with responsibility for the restructuring and monetization of assets including direct investments, listed equities, real estate, and private fund holdings.

 

Previously, he was Chief Executive Officer of The National Investor (TNI), an Abu Dhabi-based merchant banking institution. As CEO of TNI, he positioned the firm among the leading investment management and advisory companies in the GCC and focused the institution on four key areas comprising private equity, investment banking, asset management, and principal investing. Orhan was a Managing Director at Dexter Capital Group, a London-based investment firm that specializes in strategic block investments in Europe where he was responsible for the origination and execution of activist and special situations investments. Earlier in his career, Orhan was a Senior Investment Associate at J.H. Whitney, a US private equity firm where he focused on late-stage venture capital investments and leveraged buyouts in Europe.

 

Orhan began his career at Morgan Stanley where he was a member of both the equity derivatives and corporate finance groups in New York and London.  In this capacity he structured and placed a number of equity-linked derivative products and worked on various financial buyer transactions including reverse LBOs/IPOs, public and private placements of equity securities and high yield debt offerings. Orhan is a graduate of the Wharton School of the University of Pennsylvania (MBA) and the University of Virginia (BS).

Bien Kiat Tan

40 years of experience in private equity, corporate finance and management consulting

 Founder and Managing Director of Titan Capital; Former Chairman of the Board of Pacific Internet

Co-founding Partner and former Managing Director of TPG Capital Asia; built from USD 100 million to USD 6 billion dollars of capital under management

Founder and Principal of the Asian arms of A.T. Kearney and Booz Allen Hamilton; Former CEO of Ometraco Corporation

MBA, MS, Columbia University; BS (Hons), Engineering, Birmingham University

Dr. Ghida Harfouche

Ghida Harfouche has over 19 years of experience across the investment, pharmaceutical and healthcare sectors, coupled with a strong consulting expertise.

Her responsibilities include sourcing, evaluating and executing on new investment opportunities, performing financial and operational due diligence, fund reporting, as well as being actively involved in fundraising activities. She also actively participates in portfolio management, including the strategic expansion planning for portfolio and affiliated companies as well as developing exit strategies and working on exit readiness.

In a previous tenure, Ghida was a Senior Strategy Consultant at Stem-Pharma. Her role encompassed formulating effective market entry strategies, conducting feasibility and M&A analyses, leading the client relationship across Europe, and providing investment advisory services to a variety of regional and European clients.

In addition to her experience in life science consulting, Ghida has a rich scientific research background focused on pioneering novel target identification. She worked in R&D and clinical research at ‘Institut National de la Santé et de la Recherche Médicale’ (INSERM) and ‘Commissariat à l’Energie Atomique’ (CEA) in France. She received several awards during international scientific conferences. Her research findings have been published in a number of international peer-reviewed journals and she has developed a patent in oncology and photo-protection.

Ghida earned a distinguished PhD in Pharmacology, Cell and Molecular Biology from the University of Paris-Sud XI, France. Complementing her scientific acumen, she holds an MBA from Ecole Supérieure des Affaires, Lebanon, and a DESM (Diplôme d’Etudes Supérieures en Management) from ESCP-Europe, France.

Jannie Tsuei

Jannie Tsuei is a Partner in the Singapore office with a decade of transaction experience in Southeast Asia.  Prior to joining us, she led Southeast Asia healthcare investment banking at Morgan Stanley, where she drove healthcare coverage, origination, and execution efforts in the region.  She also served as Chief Operating Officer of the Southeast Asia investment banking at Morgan Stanley from 2018 to 2020. Jannie has been integrally involved in c. US$70Bn of strategic and capital transactions across North America, Asia-Pacific, and Europe.

 

Previously, Jannie worked at Sears Holdings Corporation in a general management rotational program. 

 

Jannie holds an A.B. in literature (magna cum laude) from Harvard College and holds an MBA in Finance (cum laude) from The Wharton School, the University of Pennsylvania.

Damon Jeon

Damon Jeon is a Senior Associate on TVM Capital Healthcare’s SEA investment team, based in Singapore. Prior to joining TVM Capital Healthcare, he worked as a private equity investment professional covering buyouts, growth equity, and special situations across APAC. He began his career at EY-Parthenon as a strategy consultant specializing in commercial due diligence. Damon holds a BA in Philosophy, Politics, and Economics from the University of Oxford and an MBA from INSEAD.

Tarek Mezher

Tarek Mezher is a Senior Associate on TVM Capital Healthcare’s MENA investment team, based in Dubai. He brings broad experience across the investment and banking sectors. His responsibilities include sourcing investment opportunities and liaising with management teams, as well as managing the assessment, analysis, and due diligence of transactions.

Prior to joining TVM, he worked at the European Bank for Reconstruction and Development (EBRD) in London within the Portfolio Management team, focusing on energy‑related financing and equity investments. He also served in the corporate finance division at Bank Audi in Lebanon, where he structured and syndicated financing solutions across the real estate, construction, and energy sectors in the MENA region.

Tarek holds an MBA from HEC Paris and a Master’s degree in Civil Engineering from Université Saint‑Joseph (USJ), Lebanon.

Nikhil Jham

Nikhil Jham is a member of the corporate finance team where is focused on the initial assessment of new deals, the development of business plans and due diligence. He works closely with portfolio company Manzil Healthcare Services, supporting the execution of the corporate strategy.

 

Prior to his current tenure, he spent five years in various roles in the Analytics group at ITG, an agency-only brokerage in New York City where he leveraged research, analytics and industry insights to help clients come up with customized trading strategies that minimized costs while meeting their investment objectives.

 

He holds a Bachelor of Science in Finance from the University of Virginia.